Ribociclib is an oral CDK4/6 inhibitor, approved by the FDA in 2017. CDK 4/6 inhibitors are the recommended preferred option in the treatment of advanced breast cancer. The EML expert committee recognised its potential for future inclusion and recommended to MPP to explore it for licensing.